Active surveillance in intermediate risk prostate cancer: is it safe?

被引：0
|
作者：
Krishnananthan, Nishanth [1 ]
Lawrentschuk, Nathan [1 ,2 ,3 ]
机构：
[1] Univ Melbourne, Austin Hlth, Dept Surg, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Surg Oncol, Melbourne, Vic, Australia
[3] Olivia Newton John Canc Res Inst, Melbourne, Vic, Australia
来源：
INTERNATIONAL BRAZ J UROL | 2016年 / 42卷 / 03期
关键词：
Prostatic Neoplasms; Prostate cancer; familial [Supplementary Concept; Watchful Waiting; Disease; Therapeutics; RADICAL PROSTATECTOMY; MEN; OUTCOMES; MANAGEMENT; GUIDELINE; COHORT;
D O I：
10.1590/S1677-5538.IBJU.2016.03.04
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：418 / 421
页数：4
相关论文
共 50 条
  • [31] Management of intermediate-risk prostate cancer with active surveillance: never or sometimes?
    Masic, Selma
    Washington, Samuel L., III
    Carroll, Peter R.
    [J]. CURRENT OPINION IN UROLOGY, 2017, 27 (03) : 231 - 237
  • [32] Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data
    Blas, Leandro
    Shiota, Masaki
    Eto, Masatoshi
    [J]. CANCERS, 2022, 14 (17)
  • [33] Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience
    Musunuru, Hima Bindu
    Yamamoto, Toshihiro
    Klotz, Laurence
    Ghanem, Gabriella
    Mamedov, Alexandre
    Sethukavalan, Peraka
    Jethava, Vibhuti
    Jain, Suneil
    Zhang, Liying
    Vesprini, Danny
    Loblaw, Andrew
    [J]. JOURNAL OF UROLOGY, 2016, 196 (06): : 1651 - 1657
  • [34] Active surveillance and focal therapy for low-intermediate risk prostate cancer
    Klotz, Laurence
    [J]. TRANSLATIONAL ANDROLOGY AND UROLOGY, 2015, 4 (03) : 342 - 354
  • [35] Are men with favorable intermediate-risk prostate cancer candidates for active surveillance?
    Raldow, Ann Caroline
    Zhang, Danjie
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian Joseph
    D'Amico, Anthony Victor
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [36] Active Surveillance-Is It Feasible for Intermediate-risk Localised Prostate Cancer?
    Mukherjee, Subhabrata
    Promponas, Ioannis
    Petrides, Neophytos
    Hossain, Dafader
    Abbaraju, Jayasimha
    Madaan, Sanjeev
    [J]. EUROPEAN UROLOGY OPEN SCIENCE, 2021, 24 : 17 - 24
  • [37] Active surveillance in favorable intermediate risk prostate cancer: outstanding questions and controversies
    Russell, J. Ryan
    Siddiqui, M. Minhaj
    [J]. CURRENT OPINION IN ONCOLOGY, 2022, 34 (03) : 219 - 227
  • [38] Prognostic Value of the Intermediate Risk Feature in Men with Favorable Intermediate Risk Prostate Cancer: Implications for Active Surveillance
    Sherer, M.
    Nelson, T. J.
    Courtney, P. T.
    Guram, K.
    De Moraes, G. Rodrigues
    Bagrodia, A.
    Rose, B. S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E246 - E247
  • [39] PROSTATE CANCER: Is active surveillance safe for obese patients?
    Freedland, Stephen
    Mucci, Lorelei
    [J]. NATURE REVIEWS UROLOGY, 2014, 11 (09) : 489 - 490
  • [40] Risk Group and Death From Prostate Cancer Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer
    Raldow, Ann C.
    Zhang, Danjie
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian J.
    D'Amico, Anthony V.
    [J]. JAMA ONCOLOGY, 2015, 1 (03) : 334 - 340
12345